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Introduction
The development of inhibitory anti-factor VIII (FVIII) antibodies is the major complication of replacement therapy in patients with hemophilia A, a rare X-linked recessive hemorrhagic disorder (1) . The reasons for such an immunogenicity of FVIII concentrates, as compared to other protein therapeutics, remain unclear. Different risk factors have been associated with the appearance of FVIII inhibitors including the type of F8 mutations responsible for hemophilia A, the HLA haplotypes and polymorphisms in TNFα, IL10 and CTLA-4 genes (2-5).
Inflammatory events in place or occurring at the time of therapeutic FVIII administration have also been proposed as potential risk factors. Thus, repeated joint bleeds create a chronic inflammation favoring the local recruitment and activation of antigen-presenting cells and immune effectors (3, 6) . Likewise, surgery, which in conjuncture with intensive FVIII treatment has been proposed as a risk factor for inhibitor development (7) , induces acute inflammation. Besides, the very administration of therapeutic FVIII has been controversially proposed to bring about inflammatory signals by virtue of the capacity of FVIII to induce a burst of thrombin generation, that in turn triggers proteinase-activated receptors (8, 9) .
Heme oxygenase (HO) is an essential enzyme for the catabolism of heme and has been shown to have potent anti-oxidant, cytoprotective, immuno-suppressive and anti-inflammatory properties via the production of bile pigments, carbon-monoxide (CO) and the induction of ferritin (10, 11) . Two isoforms of HO have been identified (12, 13) : HO-2 is produced constitutively, whereas HO-1 is inducible. Thus, the expression of HO-1 is normally undetectable in resting cells, but may be induced in vivo as a result of inflammation or oxidative stress, by various stimuli, such as pro-oxidative compounds, pro-inflammatory cytokines, toxins or toll-like receptor ligands (10, 12, 14) . In animal models, the pharmacological induction of HO-1 ameliorates chronic and severe inflammation (15, 16) , has beneficial effects in various autoimmune conditions (17, 18) and improves graft survival -6 - (16, 19) . HO-1 was demonstrated to participate in resolution of physiological inflammation and in wound healing (14, 20) . Accordingly, congenital defects in HO-1 expression are associated with systemic inflammation both in mice and human (20) . Recently, we demonstrated that the induction of HO-1 before the administration of FVIII to FVIII-deficient mice protects against the anti-FVIII immune response (21) . The protective effect of HO-1 induction was reverted by tin-mesoporphyrin, an inhibitor of HO-1, and was reproduced by the administration of the end-degradation products of heme by HO-1, i.e., CO and bilirubin.
The human HO-1-encoding gene (HMOX1) has been mapped to chromosome 22q12 (22) .
The transcriptional control of the gene is regulated by multiple elements, which are localized in the 5' flanking region of the promoter. To date, 3 polymorphisms in the 5' flanking region have been described: 2 single nucleotide polymorphisms -413 T>A (rs2071746) and -1135 G>A (rs2071749) and a (GT) n repeat dinucleotide length polymorphisms (23) . The number of (GT) repeats modulates gene transcription (24) ; long (GT) n repeats are associated with low levels of HO-1 expression in response to a given stimulus, while short (GT) n repeats are associated with high expression levels (25) 
Methods

Study population
Our study included 362 patients with severe hemophilia A from different hemophilia centers 
FVIII activity and FVIII inhibitory titers
FVIII activity was assessed using standard techniques. The original Bethesda method and the Nijmegen modification of the Bethesda assay were used to test for the presence or absence of FVIII-specific inhibitors in patients with hemophilia A (27) .
Genotyping of the variable (GT) n polymorphism in the promoter of the HO-1 gene
Genomic DNA was obtained from ethylene-diamine-tetra-acetic acid (EDTA) anticoagulated blood using commercial DNA isolation kits and standard salting out procedure (28) . To confirm the size of (GT) n repeats, selected samples were subjected to sequence analysis.
Statistical analysis
Associations between groups and specific classes of allele, as well as genotypes were analyzed by the two-tailed Fisher's exact test. Odds ratios (ORs) and the associated 95% confidence interval (CI) were calculated to assess the relative risk conferred by a particular allele or genotype. We also performed logistic regression analysis including the hemophiliacausing mutations, using the SAS software for Windows, version 9.3. In the logistic regression analysis, patients with inversions in intron 1 or in intron 22 were pooled in the same group to reach sufficient number of cases (29) . Statistical significance was accepted at p<0.05.
Results
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In the present study, microsatellite variability in the promoter of HO-1 was analyzed for its association with the development of FVIII inhibitors in 362 patients with severe hemophilia
A. This case-controlled study consisted of 99 severe hemophilia A patients with FVIII inhibitors and 263 patients without inhibitor. We first investigated the association of the different severe hemophilia-causing mutations with inhibitor-development in our cohort ( Table 1) . As previously reported (29, 30) , missense mutations were associated with a significantly reduced risk of inhibitor formation (OR 0.46, 95% CI 0.22-0.9, P=0.02).
Single nucleotide polymorphisms
We characterized the G(-1135)A and T(-413)A polymorphisms in the promoter of HO-1 in the case of 248 patients. The distribution of each genotype complied with the HardyWeinberg equilibrium both in cases and controls. Allele and genotype frequencies were similar to those previously described (31) . No significant association between the genotypes or the individual allele frequencies, and the development of inhibitors was observed, in agreement with a recently published genome-wide association study (GWAS) by Astermark et al (32) (Supplemental Table 1 online, p>0.05).
Allele frequencies at the polymorphic locus
The number of (GT) n repeats in the HMOX1 gene was distributed between 14 and 38 among the 362 subjects studied ( Figure 1 ). As described earlier (33), the distribution of the numbers of (GT) n showed a bimodal pattern with two main peaks located at 21 (15.2% for inhibitorpositive patients and 14.3% for inhibitor-negative patients) and 29 GT repeats (24.7% for inhibitor-positive patients and 24.5% for inhibitor-negative patients). Based on the frequency distribution in our patients cohort, and as described in previous reports (33- Table 2) . Table 3) . (Table 4) . Importantly, the association remained significant when we controlled for hemophilia-causing mutations in a multivariable logistic regression (adjusted OR 2.13, 95% CI 1.24-3.64, p=0.006). A recent genome-wide association study (GWAS) evaluated 13 331 SNPs from 1 081 genes using the Illumina iSelect platform for the association with inhibitor development in patients with hemophilia A. The study group included 833 subjects from three independent cohorts.
Genotypic frequencies in patients with or without FVIII inhibitors
Six genotypes (L/L, L/M, L/S, M/M, M/S and S/S) of (GT) n repeats were identified (
Discussion
The authors identified 53 SNPs as significant predictors of inhibitor status, thus highlighting the complexity of the anti-FVIII immune response (32) . However, the GWAS study did not find associations of SNPs located in the promoter of the HMOX1 gene with the inhibitory status of the patients, which is in agreement with the present study. Of note, the Illunina iSelect platform is not designed to investigate microsatellite polymorphisms, thus explaining that GWAS failed to identify dinucleotide length polymorphisms associated with the FVIII inhibitor status of the patients.
We and others have recently hypothesized that inflammation, either chronic due to recurrent bleeding in joints or acute during surgery or following FVIII administration, may play an adjuvant role in the anti-FVIII immune response (3, 6, 7, 36) . Intra-articular bleeding is the most common clinical manifestation of hemophilia A, and can adversely affect joints and lead -12 - to arthropathy (37) . The pathogenesis of arthropathy in hemophilia resembles inflammatory and degenerative joint disease, and is characterized by cartilage degeneration and deposition of iron, IL-1, IL-6 and TNF-a in the synovium (38) . S, M, L stand for short (<21 GT repeats), medium and long (≥30 GT repeats), respectively.
-22 - S, M, L stand for short (<21 GT repeats), medium and long (≥30 GT repeats), respectively. repeats.
